60results about "Platelet-derived growth factor" patented technology

The invention discloses a platelet growth factor derived polypeptide as well as a composition and application thereof. The amino acid sequence of the polypeptide is shown as Seq ID No: 1 (RP1601: LLKLLKKLLKKLLKK). KKIIKKL is used as a core active sequence, a variant library is designed by adopting a special design rule (AABB cycle rule), optimization is carried out by combining a polypeptide activity prediction system with a molecular docking technology, finally five candidate polypeptides are screened out, the polypeptide RP1601 has a better balance expression between drug effect and safety, and the polypeptide RP1601 is simple in structure, easy to synthesize and optimize and high in stability, and can be used for preparing a polypeptide RP1601. Therefore, the polypeptide is determined as an optimal candidate polypeptide; based on excellent anti-inflammatory, repair-promoting and anti-oxidation characteristics of the polypeptide, the invention further provides application of the polypeptide in cosmetics and medicines.

The present disclosure relates to a stable human platelet lysate composition; preferably a stable heparin-free human platelet lysate composition; methods for obtaining said composition and uses thereof.

The present invention relates to improved platelet-derived growth factor (PDGF) polypeptide variants, particularly polypeptides comprising the sequence of any one of SEQ ID NOs: 2 to 4 or a sequence having at least 80% similarity thereto, wherein the PDGF polypeptide exhibits increased stability, biological activity and / or solubility compared to the wild-type PDGF polypeptide of SEQ ID NO: 1. The present invention further provides nucleic acid sequences encoding the PDGF polypeptides of the present invention, and also provides a method for growing animal cells, comprising culturing the animal cells in a culture medium containing the PDGF polypeptide of the present invention.

The invention relates to the technical field of biological medicines, in particular to a preparation method of a stem cell factor composition for promoting scalp hair follicle regeneration. The method comprises the following steps: performing high-low oxygen cycle pre-stimulation and stepped hypoxia induction on umbilical cord mesenchymal stem cells, monitoring secretion kinetics of vascular endothelial growth factors (VEGF), hepatocyte growth factors (HGF), keratinocyte growth factors (KGF) and fibroblast growth factors 2 (FGF2) in real time, and determining the optimal collection time; performing ultrafiltration on the supernate to obtain a primary concentrated solution, optimizing the molecular weight cutoff based on the bioactivity retention rate after freezing and thawing, and concentrating to obtain a stem cell factor concentrated solution; the stem cell factor composition is obtained by combining the stem cell factor with a compound nutrition preparation, verifying in-vitro hair follicle cell proliferation / migration activity, dynamically adjusting the nutrition proportion according to the relative efficiency ratio and optimizing. According to the invention, intelligent preparation of the stem cell factor composition with multi-factor synergistic secretion, controllable process, stable activity and adjustable functions is realized.

Methods for generating multipotent radial glia-like cells and astrocyte-like cells from human pluripotent stem cells are provided, along with related compositions.

The invention provides a preparation method of a novel 34G fat product, which comprises the following steps: S1, cleaning lidocaine, epinephrine medicine, red blood cells, grease and cell debris in a fat suction substance, and removing impurities; s2, performing chylification operation on the washed fat, performing chylification for 12-24 times back and forth, and controlling the time to be within 20-30 minutes; s3, enabling the chylified fat to pass through a sieve of 60 to 100 meshes; s4, putting the fat screened by the screen into an injector, and pushing the fat to pass through a 26-29G needle; and S5, sucking fat into an injector connected with a 26-29G needle, replacing the injector with a 34G needle, and pushing out the fat of the 34G needle to obtain the novel 34G fat product. The fat product provided by the invention contains fat cells, fat stem cells, endothelial cells, smooth muscle cells, fibroblasts, immune cells, progenitor cells and growth factors and proteins secreted by various fat, and can be used for beautifying and treating various skin diseases with non-treatment purposes.

The present invention relates to the field of biomolecular pharmacology, biotechnology and genetic engineering and describes nucleic acid molecules and novel recombinant polypeptides encoded thereby, said recombinant polypeptides being PDGFR antagonists and being capable of effectively blocking the tyrosine kinase activity of PDGFR pathways. The obtained recombinant polypeptides can be used in the treatment of oncological and fibrotic diseases.

The invention provides a PDGF-B mutant, and the amino acid sequence of the PDGF-B mutant is shown as SEQ ID NO.3. The mutant has higher inducible expression concentration, and the yield and the biological activity are remarkably improved.

Provided herein are methods of engineering a cell line for reduced dependence on exogenous growth factor(s). In some embodiments, the method includes introducing into a cell one or more of: a polynucleotide comprising a coding sequence of a growth factor ligand; a polynucleotide comprising a coding sequence of a growth factor receptor; or a polynucleotide comprising a coding sequence of an activated downstream growth factor target, and culturing the cells in a cultivation infrastructure.

This invention relates to a method for producing extracellular matrix using connective tissue cell culture and to the uses of the produced extracellular matrix. More specifically, it relates to a method for culturing connective tissue cells using a serum-free and heterogeneous culture medium, which can be effectively used to increase the amount of extracellular matrix produced. Furthermore, the extracellular matrix produced by the production method of this invention is derived from human cells and does not contain any heterogeneous components such as fetal bovine serum, making it safe and useful for future development of cell therapy agents, medical supplies, medical devices for tissue treatment, or cosmetic raw materials.

To provide a safe and effective formulation for treating psoriasis.SOLUTION: The present invention relates to the use of a VEGFR gene expression inhibitor as a formulation for treating psoriasis or in its preparation. This invention effectively inhibits an abnormal expression of Rasgrp1 in skin T-cells through NBUVB irradiation, thereby inhibiting IL-17 secretion from the T-cells, thus effectively alleviating IL-17-mediated immune response in skin psoriatic lesions to achieve an effect of treating the psoriasis.SELECTED DRAWING: Figure 1

The present disclosure relates, in part, to a composition comprising a nucleic acid, wherein the nucleic acid encodes a protein which has a reduced abundance in a GTPase IMAP family 5 (GIMAP5) deficient subject or at least partially inhibits expression of a protein which has an increased abundance in a GIMAP5 deficient subject, as compared to a healthy subject. In certain embodiments, the composition is a nucleic acid-lipid particle. In certain embodiments, the composition is a polymer-based vehicle. In another aspect, the present disclosure relates to a recombinant viral vector comprising a nucleic acid encoding a protein which has a reduced abundance in a GIMAP5 deficient subject as compared to a healthy subject. In yet another aspect, the present disclosure provides a method of treating, ameliorating, and / or preventing liver disease and / or portal hypertension in a subject with administration of one or more compositions and / or vectors of the present disclosure.

The present invention provides a novel blood-derived growth-factor-containing composition. The present invention for solving the above problem is a method for preparing a growth-factor-containing composition from blood, the method comprising a step for separating platelet-rich plasma that does not contain a buffy coat component from the blood, and a step for adding citric acid and / or a salt thereof to the blood or a processed product thereof.

The invention discloses a preparation method of a platelet-derived growth factor BB. The preparation method comprises the following steps: cloning and implanting a coding gene of the platelet-derived growth factor BB into a prokaryotic expression vector to construct a recombinant prokaryotic expression vector, transferring the recombinant prokaryotic expression vector into a proper prokaryotic host cell, and culturing the prokaryotic host cell to obtain the platelet-derived growth factor BB recombinant prokaryotic expression vector. A non-soluble recombinant protein containing the platelet-derived growth factor BB is expressed, and a high-purity protein is separated. Compared with the existing reverse purification technology, the method for preparing the platelet-derived growth factor BB has the advantages that the purification steps are simple, the protein loss amount is reduced, the required purification consumables are low in price, and the cost can be greatly reduced in development and production.

The invention provides a growth factor-dextran conjugate as well as a preparation method and application thereof, the growth factor-dextran conjugate consists of a growth factor and dextran, and is obtained by coupling an amino group of the growth factor and a hydroxyl group of the dextran through a chemical reaction; the growth factor-dextran conjugate can protect the growth factor to enhance the stability of the growth factor, reduce the degradation of the growth factor in vivo and prolong the in vivo half-life period of the growth factor; coupled dextran can be combined with a cell surface receptor to promote cellular uptake of growth factors and enhance the effective action concentration of the growth factors in cells, has good biocompatibility and biological safety, and has wide application in research and development of drugs for wound repair and / or treatment of neurodegenerative diseases.

A process is provided for treating demineralized bone (DB) comprising incubating the DB with a solution of a chaotropic agent at a temperature in the range of about 12°C to about 30°C to increase the release of a bone growth factor followed by selectively removing the chaotropic agent while retaining the released growth factor and the DB. A product prepared by the process is also provided as is the use of said product to promote bone formation or bone fusion in a subject in need thereof.

Provided herein, inter alia, are genetically-modified natural killer (NK) cells capable of expressing platelet-derived growth factor (PDGF) and / or platelet-derived growth factor receptor (PDGFR); pharmaceutical compositions comprising the genetically-modified natural killer (NK) cells; methods of treating cancer with the genetically-modified natural killer (NK) cells; and methods of expanding a population of NK cells using PDGF.

Provided are compositions for stabilizing proteins, buffers comprising phosphate, histidine, or a combination thereof, and stabilizers that are sodium chloride-free and / or comprise one or more selected from the group consisting of trehalose, sucrose, and mannitol; stabilized liquid compositions of proteins comprising the stabilizing composition and the protein; and methods for preparing stabilized liquid compositions using the stabilizing composition.

The present invention relates to a method for producing bone marrow-derived endothelial precursor cells with enhanced angiogenic ability using PDGF-BB, and a method for producing a cell therapeutic agent for treating angiogenesis-related diseases using the same. Specifically, the present invention relates to a method for producing vascular endothelial precursor cells with enhanced angiogenic ability, which comprises the step of treating isolated vascular endothelial precursor cells with PDGF-BB and culturing them, a composition for promoting angiogenesis comprising vascular endothelial precursor cells and PDGF-BB as active ingredients, a method for producing a cell therapeutic agent for treating angiogenesis-related diseases, which comprises the step of mixing isolated vascular endothelial precursor cells, mesenchymal stem cells and PDGF-BB, and the cell therapeutic agent for treating angiogenesis-related diseases produced by the method.

To provide systems, methods and compositions for regenerating one or more tissues in an individual at one or more sites in need of cell and / or tissue regeneration.SOLUTION: Embodiments of the disclosure encompass methods and compositions using fibroblasts for stimulating regeneration in a first tissue site in an individual, the methods comprising the step of administering at least one regenerative composition to a second tissue site, where the second tissue site comprises the same tissue type as the first tissue site in the individual. The first and second sites are at different locations in the individual in particular embodiments. Particular embodiments comprise administering one or more compositions to an individual at a different anatomical site than a site in need, such as a joint.SELECTED DRAWING: None

The present disclosure relates to a PDGF-D prodomain, or a mutant or fusion thereof. The invention further relates to a method or application of the PDGF-D prodomain or the mutant or the fusion body thereof in inhibiting PDGFR phosphorylation, inhibiting cell proliferation stimulated by PDGF or preventing and / or treating diseases related to PDGFR phosphorylation or cell proliferation stimulated by PDGF or the method or application of the PDGF-D prodomain or the mutant or the fusion body thereof.

The present invention is directed a fusion protein comprising IL-12 and GM-CSF, which are covalently attached. The fusion protein may further comprise a transmembrane domain C-terminal to IL-12 and GM-CSF. The present invention is also directed to mRNA-LNP delivery of the fusion protein. The present invention is also directed to a method for producing membranous IL-12 and GM-CSF, and transmembrane domain in cells. The method comprises the steps of transcribing mRNA from DNA sequence encoding the fusion protein with RNA polymerase, encapsulating the mRNA in lipid nanoparticles (LNPs), transfecting the mRNA-encapsulated LNPs into cells, and translating the mRNA in the cells to produce membrane bound IL-12 fused to GM-CSF cytokine protein to stimulate immune cells and tumor microenvironment.

The invention discloses a method for enhancing the paracrine function of umbilical cord mesenchymal stem cells through gene modification and application of the method, and relates to the technical field of biology. The method comprises the following steps: connecting a target gene with an oxygen-sensitive sequence, and introducing the connected target gene and oxygen-sensitive sequence into mesenchymal stem cells through a vector, the oxygen sensitive sequence comprises a hypoxia reaction element HRE and a hypoxia inducible factor HIF-1alpha enhancer sequence, the HRE sequence is TCACGTG, and the HIF-1alpha enhancer sequence is as shown in SEQ ID NO: 1. Through specific gene modification, the level of cytokines specifically generated by the mesenchymal stem cells in the ischemic tissue can be remarkably improved, the paracrine function of the mesenchymal stem cells is enhanced, and the treatment effect is improved, so that the effectiveness and safety of gene modified mesenchymal stem cell treatment are improved.

Disclosed herein are compositions, methods, and systems for the purification and / or detection of recombinant and other proteins. In some embodiments, compositions may comprise recombinant protein with one or more sequences having substantial homology to RP-Tag Small or RP-Tag Large. In some cases, the disclosed compositions may be useful in binding or recognizing target proteins.

Provided herein are cell-penetrating peptides that efficiently target many cell types including retinal and corneal cells. These peptides can be used to deliver cargo molecules across the plasma membrane without the need for chemical coupling. Compositions and viral vectors containing these cell-penetrating peptides are also provided. Methods of using these peptides, compositions and viruses to deliver various agents to target cells and tissues are also provided.

The disclosure discloses a Saccharomyces cerevisiae lysate containing one or more cytokines, a preparation method therefor and an application thereof in cell-cultured meat, and belongs to the technical field of genetic engineering and cell-cultured meat. The disclosure provides a method for further increasing recombinant cytokine yields using the GRAS strain of S. cerevisiae recombinantly expressing a single cytokine or co-expressing a combination of cytokines through promoter optimization, knockout of endogenous protease in yeast, genome-integrated expression and other means. The yeast lysate may be directly used for muscle stem cell culture after the process such as filtration, sterilization, and cytokine concentration measurement, effectively promoting muscle stem cell proliferation. The disclosure avoids the complex purification process in the production of recombinant cytokines, reduces the cost of cytokine production, and provides new ideas for large-scale low-cost development of cell-cultured meat.

The described invention provides soft tissue grafts, hard tissue grafts, and composite soft / hard tissue grafts and methods of producing such grafts. The grafts comprise a three-dimensional carrier matrix, a growth factor composition comprising an autologous platelet-rich fibrin and a cell culture composition comprising a culture medium, a population of cells suspended in the culture medium, and cells impregnated on or in a surface of osteoconductive particles.

The invention relates to improved platelet-derived growth factor (PDGF) polypeptide variants, in particular polypeptides comprising a sequence of any one of SEQ ID NOs: 2-4 or a sequence with at least 80% similarity thereto, wherein the PDGF polypeptide exhibits increased stability, bioactivity and / or solubility compared to the wild-type PDGFB polypeptide of SEQ ID NO: 1. The invention further provides nucleic acid sequences encoding a PDGF polypeptide of the invention, and a method of growing an animal cell comprising cultivating the animal cell in a culture medium comprising a PDGF polypeptide of the invention is also provided.